Shionogi Puts up to $600m Behind BioVersys Antibiotics

Shionogi puts up to $600m behind BioVersys antibiotics

Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

Ad hoc announcement pursuant to Art. 53 LR

BioVersys and Shionogi agree to develop ansamycin leads

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Shionogi puts up to $600m behind BioVersys antibiotics – RamaOnHealthcare

Japan's Shionogi has added to its antibiotics pipeline by partnering a preclinical-stage candidate from Swiss biotech BioVersys, which specialises in

Shionogi, BioVersys team up on antibiotics for lung disease in deal worth up to $614M

BioVersys is entering a pact with Shionogi to advance the Swiss biotech’s antibiotic program targeting non-tuberculous mycobacteria, with over half a billion dollars in biobucks on the line. Shionogi is spending CHF 5 million ...